QMS signs MOU to acquire 100% of BeamOptics Scientific
As filed · QMS Medical Allied Services Limited has informed the Exchange regarding a press release dated September 28, 2026, titled "QMS Medical Allied Services to acquire Beamoptics Scientific a Pune-based diag
What happened
FactQMS Medical Allied Services signed a memorandum of understanding to acquire 100% of BeamOptics Scientific, a Pune-headquartered maker of in-vitro diagnostic devices and analytical instruments. The proposed acquisition is intended to strengthen QMS’s product business and remains conditional on mutual fulfilment of terms and conditions and NCLT approval of the composite scheme with Health Care at Home.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
Revisedwe are expecting to close this at least at Rs. 25 crores.
we expect to cross at least Rs. 60 crores, ma’am.
Change
FactImplication
CapitSignal interpretationGuidance
Withdrawnwe expect to cross at least Rs. 60 crores, ma’am.
there has been a target which has said that we need to grow by 50% every year.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- QMS has set an ambitious target of surpassing Rs. 500 crore revenue milestone by FY29 (management committed by FY29)
- The company expects the turnover to increase to Rs. 70 crore by 2031 owing to the partnership (management committed by FY31)
Evidence
- QMS Medical Allied Services Limited has informed the Exchange regarding a press release dated September 28, 2026, titled "QMS Medical Allied Services to acquire Beamoptics Scientific a Pune-based diagnostics and Analytical deep-tech company".(opens the original filing in a new tab)
- Earlier statement · Q1 FY26
- Latest statement · Q1 FY26
- Earlier statement · Q1 FY26
- Latest statement · Q1 FY26
How CapitSignal classified this
- Reasoning:
- The transaction would add diagnostic and analytical-device capabilities to QMS’s product portfolio as the company separates its services business into Saarathi Healthcare. However, the deal is not final and is contingent on stated conditions and NCLT approval.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%